Plain-English translation of NCT06505395 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new long-acting injectable medication called SYHX2008 for people with gastroenteropancreatic neuroendocrine tumors (a type of cancer that grows slowly in the digestive system or pancreas). You would receive either the new medication or an existing long-acting octreotide injection (Sandostatin LAR) to see which works better and is safer for controlling tumor growth.
The current standard treatment for these tumors works, but researchers want to see if this new medication offers improvements in how well it controls the cancer, how long it lasts in your body, or how well patients tolerate it.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to receive either the new long-acting injection or the established medication. You would visit the clinic regularly for injections and to have your tumor monitored with imaging and blood tests. The trial will measure how well the medication controls your tumor, check for side effects, and track how the medication moves through your body over time.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
China